



Antimicrobial susceptibility and epidemiological types of *Legionella pneumophila* human isolates from Italy (1987–2020)

Maria Scaturro^{a,b}, Alessio Lanni^a, Fabiola Mancini^{a,b}, Antonietta Girolamo^a, Silvia Fillo^c, Andrea Ciammaruconi^c, Florigio Lista^c, Clementina Elvezia Cocuzza^{d,e}, Rosario Musumeci^{d,e}, Christophe Ginevra^{b,f,g}, Ghislaine Descours^{b,f,g}, Sophie Jarraud^{b,f,g}, Jessica Iera^a, Paolo Visca^h, Maria Luisa Ricci^{a,b,*}

^a Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

^b ESCMID Study Group for Legionella Infections (ESGLI), Basel, Switzerland

^c Scientific Department, Army Medical Center, Rome, Italy

^d Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

^e MicroMiB Biorepository, University of Milano-Bicocca, Associated Member of the JRU MIRRI-IT, Monza, Italy

^f National Reference Centre of Legionella, Institute of Infectious Agents, Hospices Civils de Lyon, Lyon, France

^g CIRI, Centre International de Recherche en Infectiologie, Legionella Pathogenesis Team, University of Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France

^h Department of Science, University of Roma Tre, Rome, Italy

ARTICLE INFO

Article history:

Received 7 August 2024

Revised 18 December 2024

Accepted 20 December 2024

Available online 15 January 2025

Editor: Stefania Stefani

Keywords:

Legionella pneumophila

Legionnaires' disease

Antimicrobial susceptibility

Azithromycin

lpeA and *B* genes

Sequence type

ABSTRACT

Objectives: Although antimicrobial resistance has not yet emerged as an overarching problem for *Legionella pneumophila* (*L. pneumophila*) infection, the description of clinical and environmental strains resistant to fluoroquinolones and macrolides is a cause of concern. This study aimed to investigate the antimicrobial susceptibility of *L. pneumophila* human isolates in Italy.

Methods: A total of 204 *L. pneumophila* clinical isolates were tested for sensitivity to 9 antibiotics using the broth microdilution assay (BMD). All isolates were typed by sequence-based typing, and *Legionella pneumophila* serogroup 1 (Lp1) isolates by monoclonal antibody subgrouping. Minimum inhibitory concentration (MIC) data were correlated with the possible source of infection and geographical distribution. The presence of the *lpeAB* efflux pump genes was also investigated. The genome sequences of a subpopulation of isolates showing reduced susceptibility to azithromycin were also analysed.

Results: The *L. pneumophila* isolates did not show significant resistance to the tested antibiotics, although a trend toward reduced sensitivity to azithromycin was observed in a subpopulation of 46 strains, most of which belonged to sequence type 1 (ST1), the second most widespread ST in Italy. An amplicon of the expected size overlapping the *lpeAB* genes was obtained only in the 46-subpopulation above mentioned. In 4 of the 46 isolates, sequencing analysis showed the occurrence of amino-acid substitutions already described in other strains. No further mutation was found.

Conclusions: The presence of *L. pneumophila* strains with reduced susceptibility or resistance to azithromycin should be monitored to predict future trends and suggest to physicians a combined therapy with fluoroquinolones when a poor response to azithromycin is observed. © 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

© 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

* Corresponding author. Mailing address: Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy.

E-mail address: marialuisa.ricci@iss.it (M.L. Ricci).

1. Introduction

Legionella pneumophila (*L. pneumophila*) is responsible for severe pneumonia, called Legionnaires' disease, acquired by exposure to manmade devices producing contaminated aerosols, such as showers, spa pools, cooling towers, dental unit waterlines, etc. [1].

An increasing number of cases, clusters, and outbreaks has been notified in several countries, including Italy [2,3]. The infection can be acquired in the community, nosocomial, and occupational settings, with severe sequels or fatal outcomes, particularly among immunocompromised patients [4–6]. Although provisional scores for clinical and laboratory criteria have been developed, the clinical and radiological picture of Legionnaires' disease (LD) is characterized by interstitial pneumonia that cannot be distinguished from pneumonia caused by other respiratory pathogens [7]. Generally, clinical diagnostic criteria can predict the severity of infection and guide antibiotic therapy. Different and non-specific symptoms of the disease may occur, most often in immunocompromised patients, leading to an incorrect diagnosis and inappropriate antibiotic treatment [8–10]. *Legionella* infects and multiplies within alveolar macrophages, and effective antibiotics must reach the infected cells and achieve inhibitory concentrations therein. Culture-based isolation of *Legionella* from biological samples is rather infrequent due to the poor sensitivity, scarcity of respiratory samples, and time consumption. Failure in *Legionella* isolation can also be due to the collection of respiratory samples after the start of empiric antibiotic therapy, frequently based on fluoroquinolones and macrolides, or a combination of both. All these problems make it difficult to obtain *Legionella* isolates for antimicrobial susceptibility testing. Antimicrobial resistance is not yet a critical problem for *Legionella*, although the recent description of clinical and environmental strains resistant to fluoroquinolones and macrolides has raised attention to possible resistance phenomena. A *L. pneumophila* isolate resistant to fluoroquinolone, associated with antibiotic therapy failure and poor prognosis, was initially reported by Bruin et al. [11]. Both environmental and clinical *L. pneumophila* isolates endowed with decreased susceptibility to azithromycin linked to the presence of the efflux pump *lpeAB* have been documented [12–19]. These and other studies highlighted the importance to investigate the incidence of antibiotic resistance in *Legionella*, to guide the most appropriate antibiotic therapy. In this study, the broth microdilution (BMD) assay was used to provide an updated survey of antimicrobial susceptibility levels in 204 *L. pneumophila* human strains isolated in Italy. The antimicrobial susceptibility patterns were correlated with typing results, source of exposure, and geographic origin of isolates.

2. Materials and methods

2.1. Bacterial strains

From 1987 to 2020, there were 204 human isolates of *L. pneumophila* that were collected and stored at -80 ± 5 °C at the Italian reference laboratory for *Legionella*, originating from the North ($n = 129$) and from both the Center and the South ($n = 76$) of Italy with different proportions depending on the use diagnosis by culture of the hospital laboratories, but also depending on the different incidence of the disease in our country. Among the 204 *L. pneumophila* strains, 184 were serogroup 1 (Lp1), 5 were serogroup 6 (Lp6), 4 were serogroup 2 (Lp2), 3 each were for serogroups 3 (Lp3) and 10 (Lp10), and there was only 1 strain for serogroups 5, 7, 8, 9, and 14 (Lp5, Lp7, Lp8, Lp9, and Lp14, respectively). The isolates were classified according to the possible source of exposure, that is, community, nosocomial, and travel-associated. In addition, 2 reference *L. pneumophila* serogroup 1 strains, namely ATCC 33 152 and NCTC 12 821, were used as internal controls in antibiotic sensitivity assay, in accordance with the Guidance document on Antimicrobial Susceptibility Testing of *Legionella pneumophila* of the European Committee for antibiotic susceptibility testing [20].

2.2. Monoclonal antibody and sequence-based typing

The serogroup determination of the 204 *L. pneumophila* isolates was obtained using monoclonal antibodies provided by the Carl Gustav Carus University of Dresden, which also developed the Dresden monoclonal antibody (MAB) typing scheme [21,22].

This panel of MABs was created based on differences in the epitopes of Lp1 lipopolysaccharide (LPS), discriminating the following subgroups: Knoxville, Philadelphia, Benidorm, France/Allentown, Olda, Oxford, and Bellingham, Heysham, and Camperdown. Monoclonal subgrouping and genomic typing results should match for epidemiologically related strains [23,24].

The sequence type (ST) was determined for both Lp1 and non-serogroup 1 *L. pneumophila* strains by sequence-based typing (SBT) [25,26].

2.3. Antibiotics

The susceptibility of *L. pneumophila* isolates to azithromycin, clarithromycin, erythromycin, levofloxacin, moxifloxacin, ciprofloxacin, rifampicin, doxycycline, and tigecycline (Sigma-Aldrich) was tested according to the guidance *Legionella* Antimicrobial Susceptibility Testing (European Committee on Antimicrobial Susceptibility Testing [EUCAST]). The antibiotics were dissolved as recommended by the Clinical and Laboratory Standards Institute directives for antibiotic susceptibility testing and stored at -30 ± 5 °C until use [27].

2.4. Antimicrobial susceptibility test

The *L. pneumophila* human isolates and the control reference strains were thawed, plated on Buffered Charcoal Yeast Extract (BCYE; Thermo Fisher Diagnostics Limited– Altrincham, United Kingdom) agar plates, and incubated for 48 h at 37 ± 0.5 °C. Bacterial colonies were suspended in buffered yeast extract (BYE; Thermo Fisher Diagnostics Limited – Altrincham, United Kingdom) broth containing the *Legionella* growth supplement (Thermo Fisher Diagnostics Limited – Altrincham, United Kingdom) at an optical density of ca. 0.6 at 600 nm, corresponding to ca. 5×10^8 CFU/mL. The bacterial suspensions were appropriately diluted in BYE, and dispensed into 96-well microplates (Falcon, USA). Each well contained a volume of 200 µL, consisting of 100 µL of bacterial suspension at the final concentration of ca. 5×10^5 CFU/well, and 100 µL of 2-fold serial dilutions of each antimicrobial agent dissolved in BYE broth. Antimicrobials were tested at the following final concentrations (mg/L): azithromycin, 0.015 to 8; clarithromycin, ciprofloxacin, levofloxacin, and moxifloxacin, 0.0009 to 0.5; erythromycin and doxycycline, 0.03 to 16; and rifampicin, 0.00005 to 0.03. Wells containing 200 µL of uninoculated BYE broth or containing bacterial suspension without any antibiotics were used as sterility and growth controls, respectively. The microplates were incubated at 37 ± 0.5 °C without agitation, and the optical density at 570 nm was determined after 48 h by spectrophotometer (Multiskan Go, Thermo-Scientific). The minimum inhibitory concentration (MIC) values were defined as the lowest antimicrobial concentration showing 100 % growth inhibition compared with the antibiotic-free *L. pneumophila* growth control, as measured spectrophotometrically or visually. The bacterial inoculum was quantified by CFU counts on BCYE agar plates upon serial dilution in sterile distilled water. The inferred epidemiological cut-off values (ECOFF) defined were provided, although sufficient data to establish ECOFFs are not currently available for *Legionella* [20].

2.5. Screening assays of *lpeAB* gene

Polymerase chain reaction (PCR) amplification was used to screen for the presence of the *lpeAB* operon, known to encode an

efflux pump involved in a macrolide-specific reduced susceptibility [12], using total DNA extracted from *Legionella* isolates. The amplicons were generated using a previously described primer pair [14] and verified by electrophoresis on 1 % agarose gel in tris-borate-EDTA buffer. The *lpeAB* amplicon size (359 bp, overlapping the *lpeA* and *lpeB* genes) was determined by direct comparison with the O'Generuler 1 kb (Thermo Scientific, United Kingdom) molecular size ladder. Amplicon identity was determined by DNA sequencing, as outlined hereafter.

2.6. Whole genome sequencing

To identify mutations in target genes commonly involved in antibiotic resistance such as *rpoB*, *gyrA*, *gyrB*, *parC*, *rplD*, *rplV*, and the 23S rRNA gene, a subpopulation of 46 strains, consisting of 44 Lp1 and 2 non-sg1 *L. pneumophila* (Lp5 and Lp7), was analysed by whole genome sequencing (WGS). Sequencing libraries were prepared using the NextEra XT library prep kit (Illumina) and a 150-bp paired-end sequencing run was performed on the NextSeq-500 (Illumina). Reads were trimmed to keep high-quality bases (Q score > 20) using the Sickle software (version 1.33; available at <https://github.com/najoshi/sickle>). De novo assembly was carried out with the SPAdes version 3.15.0 software. Sequences were submitted to the NCBI Genbank (Project ID: PRJNA977629). Genome sequences were then checked for mutations in the targeted genes using an in-house pipeline, as described by Ginevra et al. [28]. Briefly, reads were mapped on reference sequences using minimap2 (version 2.22) and variants linked to antibiotic resistance were called using freebayes (version 1.3.5). The entire *lpeAB* operon, including the promoter region, was checked in all the 46 isolates, in looking for single mutations. To this aim, genome annotations providing the *lpeAB* positions in the contigs were obtained by PROKKA (version 1.14.5) [29] and the MAFFT's alignment was visualized by Jalview (version 2.11.3) [30].

3. Results

3.1. Epidemiological types and sources of *Legionella pneumophila* isolates

SBT differentiated the whole collection of 204 *L. pneumophila* isolates in 69 STs, among which the most frequent were ST1 ($n = 41$), ST23 ($n = 37$), ST42 ($n = 16$), ST146 ($n = 8$), ST72 ($n = 7$),

and ST435 ($n = 7$). MAb subgrouping of 184 Lp1 isolates highlighted the prevalence of the subgroup Philadelphia ($n = 97$) followed by Benidorm ($n = 26$), Knoxville ($n = 25$), Olda ($n = 14$), France-Allentown ($n = 13$), Oxford ($n = 5$), Bellingham ($n = 3$), and Heysam ($n = 1$) subgroups. Sixty-nine percent of isolates were from community-acquired cases, 24 % from nosocomial cases, and 7 % from travel-associated cases (Fig. 1).

3.2. Antimicrobial susceptibility

The bacterial inoculum was $6.1 (\pm 4.1) \times 10^5$ CFU/mL, as assessed by plate counts of 15 randomly selected test strains. The MICs of 9 antimicrobials were determined for the whole collection of 204 clinical *L. pneumophila* isolates, and the results are reported in Fig. 2, where cumulative histograms provide MIC data for Lp1 ($n = 184$) and Lp2–15 ($n = 20$) isolates. MIC ranges, MIC₅₀ and MIC₉₀, as well as the ECOFF values are shown in Table 1. Notably, all 204 isolates were sensitive to the 9 antimicrobials tested, showing susceptibility ranges close to those of the 2 reference strains. MIC values for Lp1 and Lp2–15 were quite similar for all antibiotics tested. Rifampicin was the most active antimicrobial agent against *L. pneumophila*, with the lowest MIC₅₀ and MIC₉₀ values of 0.00045 and 0.0018 mg/L, respectively. Most of the strains had the same MIC₅₀ and MIC₉₀ values for fluoroquinolones, equal to 0.03 mg/L. In the macrolide group, erythromycin and azithromycin showed the widest MIC range, and a subpopulation of 46 isolates (44 Lp1, one Lp5, and one Lp7) showed reduced susceptibility to azithromycin with MIC values ranging from 0.25 to 1 mg/L. Tigecycline had the lowest antimicrobial activity against *L. pneumophila* with the lowest MIC values detected for most isolates ranging between 16, mg/L and 32 mg/L. Doxycycline, as tigecycline, was the second antibiotic with the highest MIC₅₀ and MIC₉₀ values, 4 mg/L and 8 mg/L, respectively.

3.3. Detection of *lpeAB* genes and whole genome analysis of *Legionella pneumophila* isolates showing reduced azithromycin susceptibility

PCR amplification of the *lpeAB* efflux pump genes gave an amplicon of the expected size (359 bp) in 46 of 204 *L. pneumophila* strains tested, all showing reduced susceptibility to azithromycin (MIC range 0.25–1 mg/L; Fig. 2). Forty-four isolates were Lp1, 30 of which were Philadelphia, 6 were Olda, 6 were Oxford, 1 was




Fig. 1. (A) The histogram represents the number of each STs, determined in the collection of 204 *L. pneumophila* isolates. The pie chart represents the distribution of *L. pneumophila* serogroup 1 monoclonal subgroups. (B) The pie chart represents the settings of infection of the cases from which the strains were isolated. *L. pneumophila*, *Legionella pneumophila*; STs, sequence types.




Fig. 2. Distribution of minimum inhibitory concentrations (MICs) of the nine antibiotics, used in this study for *L. pneumophila* serogroup 1 and *L. pneumophila* 2–15 clinical strains. Asterisks indicate the MICs corresponding to the deduced epidemiological cut-off values (ECOFF). *L. pneumophila*, *Legionella pneumophila*.

Table 1

MIC ranges, MIC₅₀, MIC₉₀, and ECOFF values determined for all the Lp sg 1 and all the Lp sg 2–15 for each antibiotic.

Antimicrobial agent	Lp sg 1				Lp sg 2–15				Lp ATCC 33152	Lp NCTC 12821
	MIC range (mg/L)	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	ECOFF (mg/L)	MIC range (mg/L)	MIC ₅₀ (mg/L)	MIC ₉₀ (mg/L)	ECOFF (mg/L)	MIC range (mg/L)	MIC range (mg/L)
Azithromycin	0.03-1.00	0.125	0.5	1	0.03-0.5	0.125	0.25	0.5	0.06-0.25	0.06
Clarithromycin	0.015-0.06	0.06	0.06	0.06	0.03-0.06	0.03	0.06	0.06	0.03-0.06	0.03-0.5
Erythromycin	0.06-1	0.25	0.5	1	0.06-1	0.25	0.125	1	0.125	0.125
Ciprofloxacin	0.0075-0.06	0.03	0.03	0.06	0.015-0.06	0.015	0.03	0.03	0.015-0.03	0.015-0.03
Levofloxacin	0.015-0.06	0.03	0.03	0.06	0.0075-0.06	0.015	0.03	0.06	0.015-0.03	0.015-0.03
Moxifloxacin	0.03-0.125	0.03	0.06	0.125	0.03-0.6	0.03	0.06	0.06	0.03-0.06	0.03
Doxycycline	1-8	4	8	8	1-8	4	8	8	4-8	2-8
Tigecycline	8-32	32	32	32	8-32	16	32	32	16-32	8-32
Rifampicin	0.00022-0.0018	0.00045	0.0018	0.0018	0.00045-0.0035	0.00045	0.0018	0.0035	0.00057-0.015	0.00057-0.015

The MIC range values for LP sg 1 and LP sg 2–15 are highlighted with colours for easier comparison.

MIC ranges of reference strains are also reported.

ECOFF, epidemiological cut-off values; Lp, *Legionella pneumophila*; MIC, minimum inhibitory concentration.

Benidorm and 1 was Knoxville, and 2 were non-Lp1 (one Lp5 and one Lp7). The ST distribution in this subpopulation highlighted that most of the isolates were ST1 ($n = 34, 74\%$) followed by ST72 ($n = 6, 13\%$), ST701 ($n = 2, 4.34\%$), and one for each of the following STs, ST476, ST781, ST1520, and ST1904. The minimum spanning trees of the allelic profiles of the STs obtained for the *L. pneumophila* dataset highlighted a correlation between azithromycin MICs and STs (Fig. 3A and B), showing that the strains with the highest azithromycin MICs belonged either to ST1 or to STs differing for 1/2 alleles, such as ST72, ST476, and ST781 (Fig. 3C). The other genomes of the 46 subpopulation belong to ST701, ST1520, ST1904, and ST2212 (Fig. 4).

3.4. Whole genome sequencing

Whole genome sequences were obtained for the subpopulation of 46 isolates endowed with reduced azithromycin susceptibility.

After de novo assembly, sequences were checked for mutations implicated in antimicrobial resistance. No mutation was found in *rpoB* associated with rifamycin resistance; *gyrA* and *gyrB* encoding DNA gyrase subunits common mechanism conveying fluoroquinolones resistance; *parC* to detect point mutations preventing fluoroquinolone antibiotics from inhibiting DNA synthesis; *rplD*, *rplV*, and the 23S rRNA responsible for macrolide resistance. In the 46 subpopulation, LpeA and LpeB showed the same aminoacidic sequence as LpeA and LpeB of the Paris strain, except for 4 isolates: 486C (Lp1, ST701), 536C (Lp1, ST701), 2465 (Lp5, ST1520), and 222C (Lp7, ST1904), characterized by MIC values of 1 (both the Lp1) and 0.5 (both the non-sg1). Both LpeA and LpeB in these four strains showed the same aminoacidic substitutions, which have been already described in other strains belonging to serogroup 4 ST1973 (18). A list of these aminoacidic substitutions is reported in Table 2.




Fig. 3. Minimum spanning tree (MST) of *L. pneumophila* clinical isolates ($n = 204$) based on the allelic differences among the STs. The size of the nodes is proportional to the number of strains included in each node. On the branches, the difference in the number of different alleles is reported. (A) MICs distribution is represented by the different colours of the nodes. The highest MICs are highlighted by the red circle and arrows. (B) STs linked to the highest MICs are indicated by the red circle and arrows. *L. pneumophila*, *Legionella pneumophila*; STs, sequence types.




Fig. 4. Minimum spanning tree (MST) of the 46 *L. pneumophila* strains showing reduced susceptibility to azithromycin. Colours of the nodes indicate the MIC value as in the legend, and close to the nodes the STs are indicated. On the branches, the number of allelic differences is reported. *L. pneumophila*, *Legionella pneumophila*; STs, sequence types.

4. Discussion

This study describes for the first time the results of antimicrobial susceptibility testing of 204 clinical isolates of *L. pneumophila*, isolated in Italy over 33 years. In Italy, reporting LD has been mandatory since 1983, and although the number of reported cases is continuously increased over the years, LD incidence is not uniform across the country, with 78.7, 55.6, and 14.4 cases per million inhabitants in the northern, central, and southern regions, respectively. This is one of the reasons why in this study the isolates tested for antimicrobial sensitivity are not representative of the whole country, with isolates from the central-northern regions (95, 17 %) prevailing over those of the southern regions and the two major islands [2]. The isolates collected from community and nosocomial acquired LD cases were more represented than those from travel-associated cases. The community acquired LD cases account for the largest percentage of notified cases in Italy, followed by the travel and nosocomial-acquired cases [2]. The BMD assay is one of the methods proposed by the EUCAST Steering Commit-

tee and the American Centre for Diseases Control, and it is considered the gold standard for *L. pneumophila* antimicrobial susceptibility testing [31]. This is due to the possible interference in the antimicrobial activity of charcoal, a component added to the BCYE solid growth medium for *Legionella*, which is used for inactivating toxic lipids and peroxides [32]. Recently, Portal et al. have developed a promising solid medium without charcoal named LASARUS that showed a good agreement with BMD [33]. Because a standard protocol for testing antimicrobial sensitivity against *L. pneumophila* has not yet been developed, in this study, the BMD method was chosen to investigate the antimicrobial susceptibility of the 204 clinical *L. pneumophila* against the nine antibiotics, as suggested by the EUCAST guidance document [20]. In our experimental setting, the BMD method showed excellent reproducibility and, overall, our data confirm the susceptibility of *L. pneumophila* to the antibiotics usually used in therapy, such as fluoroquinolones and macrolides. The results are generally in good agreement with those published in the EUCAST guidance and other authors, referring to the *L. pneumophila* antimicrobial susceptibility test using BMD method both for clinical and environmental isolates, considering that the differences could also be attributed to slight variations in the methodology for testing isolates [4,17–19,34,35]. In our study, isolates belonging to Lp sg1 prevailed and only 20 belonged to Lp2–15, therefore it was not possible to adequately evaluate a significant difference in MIC values between the two groups with the exception of erythromycin, which showed the MIC₉₀ two dilution higher for Lp1 (0.5 mg/L) than for Lp2–15 (0.125 mg/L). MIC₅₀ for clarithromycin showed only one dilution of difference between Lp1 (0.06 mg/L) and Lp2–15 (0.03 mg/L). Only one dilution of difference was also observed for azithromycin MIC₉₀ between Lp1 and Lp2–15, being 0.5 mg/L and 0.25 mg/L, respectively. Similarly, the MIC₉₀ of tigecycline had only one dilution of difference between the Lp1 (32 mg/L) and Lp2–15 (16 mg/L). These data agree with other studies and show that Lp1 may have developed strategies that make these strains less susceptible to the action of antibiotics, also explaining their high prevalence in LD cases [14,17–19,34,35]. As reported by other authors [14,18,19], rifampicin was the most active antimicrobial agent against *L. pneumophila*, even using the gradient test [36]. The data obtained from fluoroquinolones are quite uniform with similar MIC values for the three antibiotics belonging to this class in all isolates tested, in good agreement with those obtained from other authors with one dilution of difference in a few cases, and rarely with two dilutions of difference [14,17–19,34]. In contrast, tigecycline (not tested by BMD method in EUCAST guidance document), a third generation glycylicycline, derived from tetracycline, showed reduced antimicrobial activity against *L. pneumophila*

Table 2
Amino acid substitutions in LpeA and LpeB of *L. pneumophila* strains compared to *L. pneumophila* Paris reference strain.

Serogroup/subgroup	Number of strains (N tot = 46)	AZ [8 - 0.015]	ST	lpp2879(lpeA)	lpp2880(lpeB)
Lp1 Benidorm	1	1	701	G9S;V26I;S34G;Y39H;S40L;E45V;S46N;I47V;P56T;S59R;T102A;K145R;S197P;A219T;L230M;D259E;T267A;S268N;L272V;I287L;L298I;A307V;E316Q;T333I;T344A;T352I;S353T;S355G	S33Q;N41H;S50N;I63V;A86T;A89T;T107A;V114I;P121Q;T127V;A244T;K247R;N257S;A259S;I296V;K309N;I327L;I380L;D418E;A488E;K503R;H507Q;N510S;L524I;D580N;A581T;A585S;N586S;H610N;S612T;I616L;V644I;S651T;H662N;T670S;V676I;A684E;A685T;N687S;N714S;I741L;S764P;V765I;H798R;G812T;T813I;T814A;M818I;I827T;K921Q;S933A;G978S;L979V;I1000L;M1002L;T1005K;G1007K;K1008I;K1009N;R1010S;C1011S;S1012K;K1013N;E1014K;-1015D;-1016L;-1017F;-1018K;-1019M;-1020K
Lp1 Philadelphia	1	1	701	G9S;V26I;S34G;Y39H;S40L;E45V;S46N;I47V;P56T;S59R;T102A;K145R;S197P;A219T;L230M;D259E;T267A;S268N;L272V;I287L;L298I;A307V;E316Q;T333I;T344A;T352I;S353T;S355G	S33Q;N41H;S50N;I63V;A86T;A89T;T107A;V114I;P121Q;T127V;A244T;K247R;N257S;A259S;I296V;K309N;I327L;I380L;D418E;A488E;K503R;H507Q;N510S;L524I;D580N;A581T;A585S;N586S;H610N;S612T;I616L;V644I;S651T;H662N;T670S;V676I;A684E;A685T;N687S;N714S;I741L;S764P;V765I;H798R;G812T;T813I;T814A;M818I;I827T;K921Q;S933A;G978S;L979V;I1000L;M1002L;T1005K;G1007K;K1008I;K1009N;R1010S;C1011S;S1012K;K1013N;E1014K;-1015D;-1016L;-1017F;-1018K;-1019M;-1020K
Lp5	1	0.5	1520	G9S;V26I;S34G;Y39H;S40L;E45V;S46N;I47V;P56T;S59R;T102A;K145R;S197P;A219T;L230M;D259E;T267A;S268N;L272V;I287L;L298I;A307V;E316Q;T333I;T344A;T352I;S353T;S355G	S33Q;N41H;S50N;I63V;A86T;A89T;T107A;V114I;P121Q;T127V;A244T;K247R;N257S;A259S;I296V;K309N;I327L;I380L;D418E;A488E;K503R;H507Q;N510S;L524I;D580N;A581T;A585S;N586S;H610N;S612T;I616L;V644I;S651T;H662N;T670S;V676I;A684E;A685T;N687S;N714S;I741L;S764P;V765I;H798R;G812T;T813I;T814A;M818I;I827T;K921Q;S933A;G978S;L979V;I1000L;M1002L;T1005K;G1007K;K1008I;K1009N;R1010S;C1011S;S1012K;K1013N;E1014K;-1015D;-1016L;-1017F;-1018K;-1019M;-1020K
Lp7	1	0.5	1904	G9S;V26I;S34G;Y39H;S40L;E45V;S46N;I47V;P56T;S59R;T102A;K145R;S197P;A219T;L230M;D259E;T267A;S268N;L272V;I287L;L298I;A307V;E316Q;T333I;T344A;T352I;S353T;S355G	S33Q;N41H;S50N;I63V;A86T;A89T;T107A;V114I;P121Q;T127V;A244T;K247R;N257S;A259S;I296V;K309N;I327L;I380L;D418E;A488E;K503R;H507Q;N510S;L524I;D580N;A581T;A585S;N586S;H610N;S612T;I616L;V644I;S651T;H662N;T670S;V676I;A684E;A685T;N687S;N714S;I741L;S764P;V765I;H798R;G812T;T813I;T814A;M818I;I827T;K921Q;S933A;G978S;L979V;I1000L;M1002L;T1005K;G1007K;K1008I;K1009N;R1010S;C1011S;S1012K;K1013N;E1014K;-1015D;-1016L;-1017F;-1018K;-1019M;-1020K
Lp1 Philadelphia	3	1	1	-	-
Lp1 Knoxville	1	0.5	1	-	-
Lp1 Olda	8	0.5	1	-	-
Lp1 Olda	1	0.5	476	-	-
Lp1 Oxford	1	0.5	781	-	-
Lp1 Oxford	1	0.5	72	-	-
Lp1 Oxford	1	0.5	1	-	-
Lp1 Philadelphia	1	1	72	-	-
Lp1 Philadelphia	16	0.5	1	-	-
Lp1 Philadelphia	5	0.25	1	-	-
Lp1 Philadelphia	4	0.5	72	-	-

Lp, *Legionella pneumophila*.

with the highest MIC values detected for most isolates ranging between 16 and 32 mg/L. Despite the low MICs, tigecycline has been demonstrated to be useful in therapy in a patient with allergies to both fluoroquinolones and macrolides, indicating that it may be administered as a safe and effective alternative therapy for treatment of LD as well as for improving the patient's condition undergoing to therapeutic treatment with moxifloxacin in combination with azithromycin [37,38]. This could be due to the greater affinity of this antimicrobial for ribosomes compared with other tetracyclines, reaching a significantly higher intracellular concentration

than doxycycline, in guinea pig models [39,40]. Doxycycline, derived from the same antibiotic family as tigecycline, was the second antibiotic with the highest MIC₅₀ and MIC₉₀ values, 4 and 8 mg/L, respectively. Other authors also found these high values for doxycycline, showing variable results for MIC₅₀ and MIC₉₀ ranging from 1 to 16 mg/L and 2 to 32 mg/L, respectively [14,17,19].

In addition, in our study, as previously reported, the macrolide group was characterized by a broader MIC distribution, with azithromycin showing the broadest [14]. Among macrolides, erythromycin showed the lowest efficacy against our strains, whereas

clarithromycin showed a higher efficacy than azithromycin, consistent with most of the data collected in the literature [14,18,19].

As for the tentative wild-type MIC distribution values, our isolates, both for Lp1 and Lp2–15, were concordant with those suggested by EUCAST for azithromycin, clarithromycin, erythromycin, moxifloxacin, rifampicin, and levofloxacin; only ciprofloxacin had 5 Lp1 isolates showing MIC values of 0.06, a higher dilution than that reported by EUCAST [20]. For levofloxacin, only the Lp14 isolate showed a quite different value (MIC = 0.5 mg/mL) from the 0.125 MIC mg/L value for Lp2–15 group reported by EUCAST guidance [20]. Similarly, one Lp1 isolate had an MIC of 0.125 mg/L for moxifloxacin (one dilution higher than the EUCAST guidance). Doxycycline was the only antibiotic with 80 % of isolates showing MIC values different from EUCAST tentative wild-type MIC distribution values. These data confirm those obtained by other authors, and we agree with Cocuzza et al. to review the tentative of wild-type MIC distribution value for doxycycline [18,19].

Concerning the azithromycin, a subpopulation of 46 strains, characterized by the presence of the efflux pump encoded by *lpeAB* operon, showed a reduced susceptibility, with 5 strains having MIC at 1 mg/L, 37 strains with MIC at 0.5 mg/L and 4 strains with MIC at 0.25 mg/L [14,18,19]. Most of these strains were Lp1 ST1 or STs differing for one allele from ST1, but there were also *L. pneumophila* non-serogroup 1 [14]. In contrast, in the remaining 158 strains with azithromycin MIC values in the expected range (0.03–0.125 mg/L), the *lpeAB* genes were absent, although other authors observed that not all isolates with decreased azithromycin MIC values harboured the *lpeAB* genes [19]. Grouping ST1 and single-locus ST1 variants, such as ST72 ($n = 6$) and ST476 ($n = 1$), all accounted for 87 % of *lpeAB*-positive isolates.

Multiple alignment of the LpA and B proteins highlighted the presence of amino acids substitutions in 4 of the 46 strains, as those already described in *L. pneumophila* serogroup 4 strains by other authors [15]. The occurrence of these substitutions in isolates other than Lp1 ST1 suggests that they may cause decreased susceptibility to azithromycin also in isolates belonging to other serogroups and STs.

Among the STs with reduced susceptibility to azithromycin, the ST701 was found in two strains (MIC = 1 mg/L) and has already been described in strains with higher MIC values [15]. Based on what has been so far reported in literature, three further STs can be added to the list of those found in azithromycin less susceptible strains (ST781, ST1520, and ST1904) and one more serogroup, the Lp7 [13,15]. Additionally, in our study, not all the ST1s showed reduced susceptibility to azithromycin, suggesting that this is not a prerogative of ST1 nor Lp1. Apart from the presence of *lpeAB* gene, no other changes were detected in the most relevant genes involved in resistance mechanisms, revealing no resistance to other antibiotics, according to the determined MIC ranges.

Regarding the MAb subgroup, 72 % of the Lp1 *lpeAB*-positive strains belonged to the most virulent MAb 3/1 subgroup, with a large prevalence of Philadelphia strains. Strains from nosocomial cases were the most frequent among the 46 subpopulation of *lpeAB*-positive strains, accounting for twice as many community-acquired cases.

In conclusion, our data confirm the results already obtained from other studies which demonstrate that the phenomenon of antimicrobial resistance, fortunately, is not yet an emergency even for Italian *L. pneumophila* clinical isolates. However, based on these data, physicians are strongly advised to pay attention to LD cases in which patients do not show rapid improvement in the clinical picture despite administration of azithromycin. It is important to emphasize that the reduced efficacy of azithromycin against *L. pneumophila* seems limited to a small but potentially growing group of STs and a predominant monoclonal subgroup.

It would be important to verify as early as possible the presence of the *lpeAB* efflux pump as well as to quickly verify whether the *L. pneumophila* strain responsible for the infection belongs to ST1 using a real-time PCR assay that specifically identifies the ST1 [41]. This recommendation should be extended also to the environmental *Legionella* monitoring practice. The recent European directive on drinking water 2020/2184 has included the *Legionella* as new parameter to be controlled in the water systems of priority buildings [42]. When applying the water safety plan approach, recommended by the new directive, the alert on the presence of certain STs or monoclonal subgroups should also be taken into account. In recent times, the application of WGS techniques allows the different virulence traits of bacterial isolates present in a water system to be easily and quickly detected. It would therefore be desirable that in the fairly near future risk assessors would use these new techniques, aimed at more rigorous actions when certain isolates are detected in artificial environments, especially when there are people at greater risk of contracting LD.

Furthermore, as a preventive action, monitoring the emergence of resistance in *Legionella* is also important due to the threat of environmental spread of antimicrobial resistance caused by the indiscriminate use of antibiotics that pose a serious risk to the human health. Some water pathogens, such as *Vibrio*, *Campylobacter*, *Salmonella*, *Shigella*, and *Escherichia coli*, and other opportunistic bacteria, have already been described as integron carriers [43]. Integrons are genetic elements involved in the spread of antibiotic resistance genes among bacterial species, and *Legionella* could also be involved in this genetic transfer. Additionally, considering that *Legionella* lives primarily in the biofilms, several studies have demonstrated that biofilms may represent an ideal substrate for the dissemination of biocide resistance cassettes within the bacterial population [43].

Finally, it has been shown that there could be a possible relationship between biocide exposure and antibiotic resistance selection [43–45] and, because *Legionella* is constantly exposed to disinfectants in engineered water systems, the occurrence of these events must be considered and carefully monitored in the future.

Funding: This research was supported by funds provided by Italian Ministry of Health for microbiological surveillance of Legionnaires' disease, grant DA87. P.V. was supported by Rome Technopole, PNRR grant M4-C2-Inv. 1.5 CUPF83B22000040006.

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] Orkisk LT, Harrison LH, Mertz KJ, Brooks MM, Bibby KJ, Stout JE. Environmental sources of community-acquired legionnaires' disease: a review. *Int J Hyg Environ Health* 2018;221(5):764–74. doi:10.1016/j.ijheh.2018.04.013.
- [2] Rota MC, Caporali MG, Giannitelli S, Urciuoli R, Scaturro M, Ricci ML. National surveillance of legionnaires' disease: results for the year 2022. *Boll Epidemiol Naz* 2023;4:25–32 [in Italian].
- [3] . European Centre for Disease Prevention and Control (ECDC). Legionnaires' disease ECDC. Annual Epidemiological Report for 2021. Stockholm, Sweden: ECDC; 2023 <https://www.cdc.gov/legionella/health-depts/surv-reporting/2016-17-surv-report-508.pdf>.
- [4] Oggioni C, Za A, Auxilia F, Faccini M, Senatore S, Vismara C, et al. *Am J Infect Control* 2016;44(10):1164–5. doi:10.1016/j.ajic.2016.03.057.
- [5] Principe L, Tomao P, Visca P. Legionellosis in the occupational setting. *Environ Res* 2017;152:485–95. doi:10.1016/j.envres.2016.09.018.
- [6] Scaturro M, Girolamini L, Pascale MR, Mazzotta M, Marino F, Errico G, et al. Case report: First report of fatal *Legionella pneumophila* and *Klebsiella pneumoniae* coinfection in a kidney transplant recipient. *Front Med (Lausanne)* 2022(9):912649 eCollection 2022. doi:10.3389/fmed.2022.912649.
- [7] Cunha BA, Wu G, Raza M. Clinical diagnosis of Legionnaire's disease: six characteristic clinical predictors. *Am J Med* 2015;128 e21–2. doi:10.1016/j.amjmed.2015.01.030.

- [8] Ceccarelli G, Venditti M, Scaturro M, Ricci ML. Clinical symptoms and treatment of Legionellosis. Legionellosis diagnosis and control in the genomic era. Ben Gurion University of the Negev, Beer Sheva, Israel: Beer Sheva, Israel: Caister Academic Press; 2020. p. 173–86. Moran-Gilad J, Gibbs RE, eds.
- [9] Serio G, Fortarezza F, Pezzuto F, Santacroce L, Nazzaro P, Bellitti E, et al. Legionnaires' disease arising with hirsutism: case report of an extremely confusing event. *BMC Infect Dis* 2021;21(1):532. doi:10.1186/s12879-021-06247-9.
- [10] Holloway KD, Amisha F, Post G, Goraya H. Hairy cell leukemia (HCL) presenting as severe acute respiratory distress syndrome (ARDS) with Legionella pneumophila: coincidence or causation? *Cureus* 2023;15(11):e48317. doi:10.7759/cureus.48317.
- [11] Bruin JP, Koshkolda T, Ijzerman EP, Lück C, Diederer BM, Den Boer JW, et al. Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia. *Antimicrob Chemother* 2014;69(10):2869–71 Epub 2014 Jun 4. doi:10.1093/jac/dku196.
- [12] Massip C, Descours G, Ginevra C, Doublet P, Jarraud S, Gilbert C. Macrolide resistance in Legionella pneumophila: the role of *LpeAB* efflux pump. *J Antimicrob Chemother* 2017;72:1327–33. doi:10.1093/jac/dkw594.
- [13] Rahimi B, Vesal A. Antimicrobial resistance properties of Legionella pneumophila isolated from the cases of lower respiratory tract infections. *Biom Pharm J* 2017;10:59–65. doi:10.13005/bpj/1081.
- [14] Vandewalle-Capo M, Massip C, Descours G, Charavit J, Chastang J, Billy PA, et al. Minimum inhibitory concentration (MIC) distribution among wild-type strains of Legionella pneumophila identifies a subpopulation with reduced susceptibility to macrolides owing to efflux pump genes. *Int J Antimicrob Agents* 2017;50:684–9. doi:10.1016/j.ijantimicag.2017.08.001.
- [15] Natás OB, Brekken AL, Bernhoff E, Hetland MAK, Löhr IH, Lindemann PC. Susceptibility of Legionella pneumophila to antimicrobial agents and the presence of the efflux pump *LpeAB*. *J Antimicrob Chemother* 2019;74:1545–50. doi:10.1093/jac/dkz081.
- [16] Jia X, Ren H, Nie X, Li Y, Li J, Qin T. Antibiotic resistance and azithromycin resistance mechanism of Legionella pneumophila serogroup 1 in China. *Antimicrob Agents Chemother* 2019;63:e00768–19. doi:10.1128/AAC.00768-19.
- [17] Cruz C, Rodrigues L, Fernandes F, Santos R, Paixão P, Chasqueira MJ. Antibiotic susceptibility pattern of Portuguese environmental Legionella isolates. *Front Cell Infect Microbiol* 2023;13:114115. doi:10.3389/fcimb.2023.114115.
- [18] Cocuzza CE, Martinelli M, Perdoni F, Giubbì C, Vinetti MEA, Calaresu E, et al. Antibiotic susceptibility of environmental legionella pneumophila strains isolated in Northern Italy. *Int J Environ Res Public Health* 2021;18(17):9352. doi:10.3390/ijerph18179352.
- [19] Yang JL, Sun H, Zhou X, Yang M, Zhan XY. Antimicrobial susceptibility profiles and tentative epidemiological cutoff values of Legionella pneumophila from environmental water and soil sources in China. *Front Microbiol* 2022;13:924709 eCollection 2022. doi:10.3389/fmicb.2022.924709.
- [20] European Committee on Antimicrobial Susceptibility Testing, ESCMID. Guidance document on Antimicrobial Susceptibility Testing of Legionella pneumophila, 30 May 2021. (https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Legionella_guidance_note_-_20210528.pdf)
- [21] Helbig JH, Kurtz JB, Pastoris MC, Pelaz C, Lück PC. Antigenic lipopolysaccharide components of Legionella pneumophila recognized by monoclonal antibodies: possibilities and limitations for division of the species into serogroups. *J Clin Microbiol* 1997;35(11):2841–5. doi:10.1128/JCM.35.11.2841-2845.1997.
- [22] Helbig JH, Bernander S, Castellani Pastoris M, Etienne J, Gaia V, Lauwers S, et al. Pan-European study on culture-proven Legionnaires' disease: distribution of Legionella pneumophila serogroups and monoclonal subgroups. *Eur J Clin Microbiol Infect Dis* 2002;21(10):710–16 Epub 2002. doi:10.1007/s10096-002-0820-3.
- [23] Fontana S, Scaturro M, Rota MC, Caporali MG, Ricci ML. Molecular typing of Legionella pneumophila serogroup 1 clinical strains isolated in Italy. *Int J Med Microbiol* 2014;304(5–6):597–602 Epub 2014 Apr 26. doi:10.1016/j.ijmm.2014.04.004.
- [24] Scaturro M, Fontana S, Crippa S, Caporali MG, Seyler T, Veschetti E, et al. An unusually long-lasting outbreak of community-acquired Legionnaires' disease, 2005–2008, Italy. *Epidemiol Infect* 2015;143(11):2416–25 Epub 2014 Nov 27. doi:10.1017/S0950268814003094.
- [25] Gaia V, Fry NK, Afshar B, Lück PC, Meunier H, Etienne J, et al. Consensus sequence-based scheme for epidemiological typing of clinical and environmental isolates of Legionella pneumophila. *J Clin Microbiol* 2005;43(5):2047–52. doi:10.1128/JCM.43.5.2047-2052.2005.
- [26] Ratzow S, Gaia V, Helbig JH, Fry NK, Lück PC. Addition of neuA, the gene encoding N-acetylneuraminyl transferase, increases the discriminatory ability of the consensus sequence-based scheme for typing Legionella pneumophila serogroup 1 strains. *J Clin Microbiol* 2007;45(6):1965–8. doi:10.1128/JCM.00261-07.
- [27] Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement. CLSI document M100-S26. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
- [28] Ginevra C, Beraud L, Pionnier I, Sallabery K, Bentayeb H, Simon B, et al. Detection of highly macrolide-resistant Legionella pneumophila strains from a hotel water network using systematic whole-genome sequencing. *J Antimicrob Chemother* 2022;77(8):2167–70. doi:10.1093/jac/dkac173.
- [29] Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 2014;30(14):2068–9. doi:10.1093/bioinformatics/btu153.
- [30] Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. *Bioinformatics* 2009;25(9):1189–91. doi:10.1093/bioinformatics/btp033.
- [31] Portal E, Descours G, Ginevra C, Mentasti M, Afshar B, Chand M, et al. Legionella antibiotic susceptibility testing: is it time for international standardization and evidence-based guidance? *J Antimicrob Chemother* 2021;76(5):1113–16. doi:10.1093/jac/dkab027.
- [32] García MT, Pelaz C, Giménez MJ, Aguilar L. In vitro activities of gemifloxacin versus five quinolones and two macrolides against 271 Spanish isolates of Legionella pneumophila: influence of charcoal on susceptibility test results. *Antimicrob Agents Chemother* 2000;44(8):2176–8. doi:10.1128/AAC.44.8.2176-2178.2000.
- [33] Portal E, Sands K, Portnojs A, Chalker VJ, Spiller OB. Legionella antimicrobial sensitivity testing: comparison of microbroth dilution with BCYE and LASARUS solid media. *J Antimicrob Chemother* 2021;76:1197–204. doi:10.1093/jac/dkaa535.
- [34] Xiong L, Yan H, Shi L, Mo Z. Antibiotic susceptibility of Legionella strains isolated from public water sources in Macau and Guangzhou. *J Water Health* 2016;14(6):1041–6. doi:10.2166/wh.2016.056.
- [35] Pappa O, Chochlakakis D, Sandalakis V, Dioli C, Psaroulaki A, Mavridou A. Antibiotic resistance of Legionella pneumophila in clinical and water isolates - a systematic review. *Int J Environ Res Public Health* 2020;17:5809. doi:10.3390/ijerph17165809.
- [36] De Giglio O, Napoli C, Lovero G, Diella G, Rutigliano S, Caggiano G, et al. Antibiotic susceptibility of Legionella pneumophila strains isolated from hospital water systems in Southern Italy. *Environ Res* 2015;142:586–90. doi:10.1016/j.envres.2015.08.013.
- [37] Arget M, Kosar J, Suen B, Peermohamed S. Successful treatment of Legionnaires' disease with tigecycline in an immunocompromised man with a legion of antibiotic allergies. *Cureus* 2019;11:e4577. doi:10.7759/cureus.4577.
- [38] Fan FF, Yu X, Shuai ZW, Hu XY, Pang M, Shi YW. Diagnosis and treatment of water-contaminated severe Legionella pneumonia with digestive symptoms as the first symptom: a case report and review of the literature. *Infect Drug Resist* 2023;16:323–8 eCollection 2023. doi:10.2147/IDR.S394965.
- [39] Bauer G, Berens C, Projan SJ, Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe²⁺ cleavage of 16S rRNA. *J Antimicrob Chemother* 2004;53(4):592–9. doi:10.1093/jac/dkh125.
- [40] Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. *Antimicrob Agents Chemother* 2003;47(2):533–40. doi:10.1128/AAC.47.2.533-540.2003.
- [41] Ginevra C, Chastang J, David S, Mentasti M, Yakunin E, Chalker VJ, et al. A real-time PCR for specific detection of the Legionella pneumophila serogroup 1 ST1 complex. *Clin Microbiol Infect* 2020;26:514.e1–514.e6. doi:10.1016/j.cmi.2019.09.002.
- [42] Directive (EU) 2020/2184 of the European Parliament and of the council of 16 December 2020 on the quality of water intended for human consumption. 2020. Available at: <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32020L2184>.
- [43] Kaushik M, Kumar S, Kapoor RK, Gulati P. Integrins and antibiotic resistance genes in water-borne pathogens: threat detection and risk assessment. *J Med Microbiol* 2019;68:679–92. doi:10.1099/jmm.0.000972.
- [44] Charron R, Boulanger M, Briandet R, Bridier A. Biofilms as protective cocoons against biocides: from bacterial adaptation to One Health issues. *Microbiology (Reading)* 2023;169(6):001340. doi:10.1099/mic.0.001340.
- [45] Merchel Piovesan Pereira B, Wang X, Tagkopoulou I. Biocide-induced emergence of antibiotic resistance in Escherichia coli. *Front Microbiol* 2021;12:640923. doi:10.3389/fmicb.2021.640923.